Theravance Biopharma Inc (TBPH)
8.755
+0.10
(+1.10%)
USD |
NASDAQ |
Jun 21, 16:00
8.76
0.00 (0.00%)
After-Hours: 20:00
Theravance Biopharma Cash from Operations (Quarterly): -1.022M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -1.022M |
| December 31, 2023 | -0.854M |
| September 30, 2023 | -2.486M |
| June 30, 2023 | -12.44M |
| March 31, 2023 | -11.22M |
| December 31, 2022 | -124.06M |
| September 30, 2022 | -22.14M |
| June 30, 2022 | -14.73M |
| March 31, 2022 | -26.07M |
| December 31, 2021 | -42.43M |
| September 30, 2021 | -45.45M |
| June 30, 2021 | -50.11M |
| March 31, 2021 | -69.86M |
| December 31, 2020 | -64.92M |
| September 30, 2020 | -77.03M |
| June 30, 2020 | -53.35M |
| March 31, 2020 | -55.10M |
| December 31, 2019 | -64.35M |
| September 30, 2019 | -44.62M |
| June 30, 2019 | -48.03M |
| March 31, 2019 | -81.19M |
| December 31, 2018 | -52.18M |
| September 30, 2018 | -48.98M |
| Date | Value |
|---|---|
| June 30, 2018 | -61.54M |
| March 31, 2018 | 49.82M |
| December 31, 2017 | -44.20M |
| September 30, 2017 | -62.30M |
| June 30, 2017 | -44.52M |
| March 31, 2017 | -50.03M |
| December 31, 2016 | -28.11M |
| September 30, 2016 | -12.43M |
| June 30, 2016 | -32.14M |
| March 31, 2016 | -26.31M |
| December 31, 2015 | -33.75M |
| September 30, 2015 | -31.98M |
| June 30, 2015 | -46.61M |
| March 31, 2015 | -56.51M |
| December 31, 2014 | -42.54M |
| September 30, 2014 | -36.38M |
| June 30, 2014 | -51.44M |
| March 31, 2014 | -44.80M |
| December 31, 2013 | -35.19M |
| September 30, 2013 | -32.94M |
| June 30, 2013 | -24.34M |
| March 31, 2013 | -28.49M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-124.06M
Minimum
Dec 2022
-0.854M
Maximum
Dec 2023
-41.51M
Average
-45.03M
Median
Cash from Operations (Quarterly) Benchmarks
| Zoetis Inc | 595.00M |
| Corcept Therapeutics Inc | 23.76M |
| Nektar Therapeutics | -47.89M |
| Stereotaxis Inc | -2.346M |
| Cara Therapeutics Inc | -30.45M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 17.03M |
| Cash from Financing (Quarterly) | -1.716M |
| Free Cash Flow | -18.44M |
| Free Cash Flow Per Share (Quarterly) | -0.0231 |
| Free Cash Flow to Equity (Quarterly) | -1.113M |
| Free Cash Flow to Firm (Quarterly) | -1.113M |
| Free Cash Flow Yield | -4.08% |